Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

Rhea-AI Summary

Tenaya Therapeutics (NASDAQ: TNYA), a clinical-stage biotech company focused on developing curative therapies for heart disease, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The company's CEO, Faraz Ali, will engage in a fireside chat on Tuesday, August 12, 2025 at 11:30 am ET.

Investors can access the live webcast through Tenaya's website's Investor section, with a replay available for approximately 30 days after the event.

News Market Reaction – TNYA

+0.86%

1 alert

+0.86% News Effect

On the day this news was published, TNYA gained 0.86%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in the Canaccord Genuity 45^th Annual Growth Conference on Tuesday, August 12, 2025 at 11:30 am ET.

The live webcast of the fireside chat may be accessed from the Investors section of Tenaya’s website. An archived replay will be available on the Tenaya website for approximately 30 days following the live event.

About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya’s pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) and TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Tenaya has employed a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of novel medicines based on genetic insights, including TN-301, a clinical-stage small molecule HDAC6 inhibitor for the potential treatment of heart failure and related cardio/muscular disease, and multiple early-stage programs in preclinical development aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit www.tenayatherapeutics.com.

Tenaya Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com

Investors
Anne-Marie Fields
Precision AQ
annemarie.fields@precisionaq.com

FAQ

When is Tenaya Therapeutics (TNYA) presenting at the Canaccord Genuity Conference?

Tenaya's CEO will participate in a fireside chat on Tuesday, August 12, 2025 at 11:30 am ET.

How can investors access Tenaya Therapeutics' (TNYA) Canaccord conference presentation?

Investors can access the live webcast through the Investors section of Tenaya's website, with a replay available for approximately 30 days after the event.

Who will represent Tenaya Therapeutics (TNYA) at the Canaccord Genuity Conference?

Faraz Ali, Tenaya's Chief Executive Officer, will represent the company at the conference.

What is Tenaya Therapeutics' (TNYA) main business focus?

Tenaya is a clinical-stage biotechnology company focused on discovering, developing, and delivering potentially curative therapies for heart disease.